[A case report of an advanced and recurrent stomach cancer in a patient manifesting response to cisplatinum-based chemotherapy].
In an advanced stomach cancer with recurrence of regional lymph node metastasis, cis-diamminedichloro-platinum (CDDP) was administered intravenously (IV) according to the following doses and schedules. This treatment schedule consisted of CDDP at a dosage of 100 mg/body/time. This dosage was infused seven times for 24 months (total CDDP dose, 700 mg/body). The overall response rate to chemotherapy was determined as follows. Partial response (PR) was defined as a reduction of at least 50% in the sum of the products of the two greatest perpendicular diameters of all measurable lesions within 15 months of commencing therapy and the absence of disease progression elsewhere. The 56-year-old, male patient is being treated with an outpatient regimen at our Hospital.
Takamura
H
H
Third Dept. of Surgery, Tokyo Medical College.
Kimura
K
K
Suzuki
K
K
Fukaya
Y
Y
Saito
S
S
Tsurui
S
S
Shiraishi
Y
Y
Yamazaki
T
T
D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy*
D002945:Cisplatin